Information in the news releases is current on the date of the announcement, but is subject to change without prior notice.
December 13, 2013
LAUNCH OF MEASUREMENT REAGENT KIT “E TEST ｢TOSOH｣ Ⅱ (PIVKA-Ⅱ)” FOR USE WITH TOSOH AIA SYSTEMS IN DETECTING HEPATOCELLULAR CARCINOMA DIAGNOSTIC-AID MARKER PIVKA-Ⅱ/DCP IN JAPAN
December 5, 2013
EISAI TO PRESENT NEW RESEARCH ON HALAVEN® (ERIBULIN) AT 36TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM
November 29, 2013
Notification Regarding Execution of Business Transfer Agreement to Transfer Business Operations at Eisai Misato Plant to Bushu Pharmaceuticals Ltd.
November 29, 2013
Notification Regarding Implementation of Voluntary Retirement Program
November 29, 2013
EISAI PRODUCT CREATION SYSTEMS (EPCS) UNDERGOES TRANSFORMATION WITH AIM OF FURTHER FOCUSING AND STRENGTHENING PRODUCT CREATION CAPABILITIES
November 28, 2013
EISAI SUBMITS APPLICATION FOR PROTON PUMP INHIBITOR PARIET® IN JAPAN SEEKING INDICATION EXPANSION FOR PREVENTION OF RECURRENT GASTRIC OR DUODENAL ULCER CAUSED BY LOW-DOSE ASPIRIN THERAPY AND APPROVAL OF NEW FORMULATION
November 25, 2013
EISAI TO RECEIVE JAPAN MARKETING AUTHORIZATION HOLDER LICENSE FROM NOBELPHARMA FOR ANTINEOPLASTIC AGENT GLIADEL® 7.7 mg IMPLANT
November 25, 2013
EISAI JOINS GROUNDBREAKING TUBERCULOSIS DRUG ACCELERATOR PARTNERSHIP TO DISCOVER NEW TUBERCULOSIS DRUGS
November 20, 2013
A NEW STRATEGY FOR 24-HOUR PROTECTION FROM VIRUSES IN THE HOME! EISAI ANNOUNCES LAUNCH OF NEW “CRYSTAL VEIL FUITE BOKIN 24” WET WIPES CONTAINING LONG-ACTING ANTIMICROBIAL AGENT ETAK®
HELPS PREVENT VIRUSES AND BACTERIA FROM ADHERING TO HOUSEHOLD SURFACES
November 12, 2013
EISAI MAKES DONATION TO VICTIMS OF TYPHOON HAIYAN IN PHILIPPINES
November 8, 2013
EISAI ENTERS GLOBAL AGREEMENT WITH BROAD INSTITUTE TO DEVELOP NEW DRUGS FOR NEGLECTED TROPICAL DISEASES AND TUBERCULOSIS
DRUG DISCOVERY PROJECT FOR CHAGAS DISEASE AWARDED GHIT FUND GRANT
November 8, 2013
EISAI EXPANDS MARKETING AND SUPPLY AGREEMENT FOR ANTIOBESITY AGENT LORCASERIN TO INCLUDE MOST COUNTRIES WORLDWIDE
AIMS TO ESTABLISH WEIGHT MANAGEMENT GLOBAL STANDARD THAT INCLUDES DRUG THERAPY
October 31, 2013
EISAI SUBMITS APPLICATION TO EXPAND INDICATION OF ANTI-ALZHEIMER'S AGENT ARICEPT ® AS TREATMENT FOR DEMENTIA WITH LEWY BODIES IN JAPAN
October 29, 2013
EISAI BEGINS FREE SUPPLY OF DIETHYLCARBAMAZINE IN LINE WITH ITS GLOBAL COMMITMENT TO ELIMINATE LYMPHATIC FILARIASIS
FIRST SHIPMENT TO BENEFIT MORE THAN 6 MILLION PEOPLE IN 4 ENDEMIC COUNTRIES
October 16, 2013
EISAI TO EXPAND ANTIOBESITY AGENT BELVIQ® SALES FORCE IN U.S.
October 3, 2013
EISAI RECEIVES EUROPEAN COMMISSION APPROVAL ON USE OF ANTIEPILEPTIC AGENT ZONEGRAN® IN PEDIATRIC PATIENTS
October 1, 2013
EISAI ANNOUNCES LAUNCH OF ANTICANCER AGENT HALAVEN® IN INDIA
October 1, 2013
EISAI PRESENTS ADDITIONAL ANALYSIS FINDINGS ON HALAVEN® (ERIBULIN) AT EUROPEAN CANCER CONGRESS 2013
September 25, 2013
EISAI SELECTED FOR MEMBERSHIP OF DOW JONES SUSTAINABILITY ASIA PACIFIC INDEX, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT
September 18, 2013
EISAI'S U.S. RESEARCH SUBSIDIARY H3 BIOMEDICINE ENTERS INTO COLLABORATIVE AGREEMENT WITH SELVITA TO CREATE NOVEL ANTICANCER AGENTS
September 12, 2013
EISAI ANNOUNCES LAUNCH OF ANTICANCER AGENT HALAVEN® AS COMPANY'S FIRST PRODUCT IN RUSSIA
September 11, 2013
EISAI ANNOUNCES LAUNCH OF SELBELLE® UKON 27 PLUS GRANULE 30 mg OF HIGH-ABSORPTION CURCUMIN FOR APPROX. 27 TIMES THE ABSORPTION!
August 29, 2013
EISAI ENTERS COMMUNITY DEVELOPMENT PARTNERSHIP AGREEMENT WITH CITY OF YOKOHAMA TO PROMOTE LOCAL DEMENTIA SUPPORT INITIATIVES
August 27, 2013
EISAI RECEIVES PREQUALIFICATION FROM WORLD HEALTH ORGANIZATION FOR LYMPHATIC FILARIASIS MEDICINE DIETHYLCARBAMAZINE
SUPPLY FROM VIZAG PLANT, INDIA TO 24 ENDEMIC COUNTRIES TO BEGIN THIS YEAR
August 27, 2013
EISAI ANNOUNCES LAUNCH OF HIGHER-DOSE ARICEPT® 23 mg TABLET FOR MODERATE-TO-SEVERE ALZHEIMER鈥橲 DISEASE IN SOUTH KOREA
REALIZES FURTHER CONTRIBUTION TO PATIENTS WITH DEMENTIA IN ASIA REGION
August 21, 2013
EISAI RECEIVES APPROVAL TO MARKET PARIET® TRIPLE FORMULATION PACKS RABECURE® 400 AND 800 AND RABEFINE®, FOR PRIMARY AND SECONDARY H. PYLORI ERADICATION RESPECTIVELY, IN JAPAN
August 1, 2013
CONTINUATION OF 鈥淧OLICY FOR PROTECTION OF THE COMPANY'S CORPORATE VALUE AND COMMON INTERESTS OF SHAREHOLDERS (SHAREHOLDER RIGHTS PLAN)鈥�
July 29, 2013
EISAI RECEIVES POSITIVE OPINION FROM EMA'S CHMP ON USE OF ANTIEPILEPTIC AGENT ZONEGRAN® IN PEDIATRIC PATIENTS
July 19, 2013
Notice Regarding Transfer of Shares of Eisai Subsidiary
June 25, 2013
EISAI TO SUSPEND TEMPORARILY COMMERCIAL DISTRIBUTION OF ANTIEPILEPTIC DRUG FYCOMPA® IN GERMANY
COMPANY WILL CONTINUE TO ENSURE ACCESS TO THE DRUG FOR PATIENTS IN NEED OF FYCOMPA TREATMENT
June 25, 2013
EISAI ANNOUNCES LAUNCH OF NEW DRY SYRUP FORMULATION OF ALZHEIMER'S DISEASE TREATMENT ARICEPT® IN JAPAN
June 17, 2013
EISAI TO MAKE NEW INVESTMENT IN EXPANSION OF GLOBAL PACKAGING FACILITY AT HATFIELD PRODUCTION PLANT IN U.K.
June 14, 2013
AbbVie and Eisai Announce HUMIRA® Pre-filled Syringe 40 mg / 0.8 mL, a Fully Human Monoclonal Anti-TNF-α Antibody Formulation, Has Received Approval for the Treatment of Moderate to Severe Ulcerative Colitis (UC) in Japan
HUMIRA Becomes the First and Only Self-Injectable Biologic Therapy for the Treatment of Moderate to Severe UC
June 11, 2013
EISAI TO LAUNCH CHOCOLA BB® SPARKLING VITAMIN KYUTTO LEMON FLAVOR
CONTAINS 5 INGREDIENTS THAT HELP BRING OUT BEAUTY FROM WITHIN & REDUCED CALORIES
June 10, 2013
EISAI CONFIRMS THERAPEUTIC EFFECTS OF LENVATINIB IN PATIENTS WITH MELANOMA IN STRATEGIC COLLABORATION WITH QUINTILES TO DEVELOP EISAI ANTICANCER COMPOUNDS
June 3, 2013
EISAI PRESENTS NEW QUALITY OF LIFE FINDINGS IN PATIENTS WITH METASTATIC BREAST CANCER FROM HALAVEN® (ERIBULIN) VERSUS CAPECITABINE STUDY AT 49TH ASCO ANNUAL MEETING
May 30, 2013
Notification Regarding Partial Amendment to the Articles of Incorporation
May 30, 2013
Notification Regarding the Completion of the Disposal of Treasury Stock Through Third-Party Allotment in Accordance with the Introduction of Performance-Related Stock Compensation System
May 28, 2013
EISAI ANNOUNCES LAUNCH OF ANTIEPILEPTIC AGENT INOVELON® TABLETS 100 mg, 200 mg IN JAPAN
May 24, 2013
AbbVie and Eisai Announce HUMIRA® Pre-filled Syringe Has Received Approval for the Treatment of Intestinal Behçet's Disease in Japan
HUMIRA is the First Biologic Approved to Treat Intestinal Behçet's Disease in Japan
May 17, 2013
EISAI TO PRESENT NEW RESEARCH ON ONCOLOGY PRODUCTS AND PIPELINE AT 49TH ASCO ANNUAL MEETING
May 13, 2013
Notification Regarding the Disposal of Treasury Stock through Third-Party Allotment in Accordance with the Introduction of Performance-Related Stock Compensation System
May 13, 2013
Notification Regarding the Introduction of a Performance-Related Stock Compensation System in Accordance with the Revision of the Compensation System for the Corporate Officers of the Company
May 8, 2013
PUBLICATION IN FEDERAL REGISTER TOMORROW MOVES BELVIQ® CLOSER TO LAUNCH
May 7, 2013
EISAI FILES FOR INDICATION EXPANSION OF ANTICANCER AGENT HALAVEN® WITH EUROPEAN MEDICINES AGENCY
SEEKS EARLIER-LINE USE IN TREATMENT OF METASTATIC BREAST CANCER
April 26, 2013
EISAI SUPPORTS EARTHQUAKE RELIEF EFFORTS IN SICHUAN, CHINA
April 25, 2013
EISAI TO ESTABLISH NEW PARENTERAL FACILITY IN CHINA
April 17, 2013
EISAI RECEIVES MANUFACTURING AND MARKETING AUTHORIZATION FOR VASCULAR EMBOLIZATION DEVICE DC BEAD® IN JAPAN
April 10, 2013
EISAI ANNOUNCES PRECLINICAL RESEARCH FINDINGS SUGGESTING NOVEL INHIBITORY EFFECT ON TUMOR METASTASIS FOR ANTICANCER AGENT HALAVEN® AT AACR 104TH ANNUAL MEETING
April 8, 2013
EISAI CO-ESTABLISHES THE GLOBAL HEALTH INNOVATIVE TECHNOLOGY FUND
AIMS TO ADVANCE DEVELOPMENT OF NEW HEALTH TECH FOR THE DEVELOPING WORLD
April 5, 2013
EISAI ESTABLISHES PHARMA SALES SUBSIDIARY IN MOSCOW AHEAD OF PLANNED DIRECT SALES LAUNCH IN RUSSIA
March 27, 2013
NEW DRUG APPLICATION FOR PEDIATRIC FORMULATION ACIPHEX® SPRINKLE™ APPROVED BY U.S. FDA
March 26, 2013
EISAI TO LAUNCH BOTULINUM TOXIN TYPE B NEUROMUSCULAR-BLOCKING AGENT NERBLOC® INTRAMUSCULAR INJECTION 2500 UNITS IN JAPAN
March 25, 2013
EISAI RECEIVES MANUFACTURING AND MARKETING AUTHORIZATION FOR ANTIEPILEPTIC AGENT INOVELON® IN JAPAN
March 15, 2013
SYMBIO AND EISAI ANNOUNCE REMOVAL OF TREAKISYM® INJECTION 100 MG ALL CASES SURVEILLANCE CONDITION FOR JAPAN MARKETING APPROVAL
March 5, 2013
EISAI ANNOUNCES LAUNCH OF BI CHOCOLA COLLAGEN AND BI CHOCOLA COLLAGEN GELÉE
February 28, 2013
NEW INDICATION APPROVED IN JAPAN FOR LYRICA® CAPSULES
February 28, 2013
Ajinomoto Pharmaceuticals and Eisai Announce Japan Launch of Antiosteoporotic Agent Once-Monthly Formulation Actonel® 75 mg Tablets
February 26, 2013
EISAI ANNOUNCES LAUNCH OF CHOCOLA BB® SPARKLING + FIBER,CONTAINING 5 INGREDIENTS THAT HELP BRING OUT BEAUTY FROM WITHIN
INCLUDES DIETARY FIBER EQUIVALENT TO 1.6 CELERY STALKS
February 21, 2013
EISAI’S U.S. SUBSIDIARY EISAI INC. TO DIVEST U.S. RIGHTS FOR TARGRETIN® TO VALEANT
February 21, 2013
Helicobacter pylori Gastritis Approved as Additional Indication in Japan for Helicobacter pylori Eradication by Triple Therapy with Proton Pump Inhibitor
February 8, 2013
EISAI'S TAIWAN SUBSIDIARY EISAI TAIWAN INC. TO DIVEST TAINAN PLANT TO TAIWANESE PHARMA COMPANY BORA
January 11, 2013
EISAI ANNOUNCES RESULTS OF PHASE Ⅲ STUDY OF ANTICANCER AGENT FARLETUZUMAB IN PATIENTS WITH RELAPSED PLATINUM-SENSITIVE OVARIAN CANCER
January 8, 2013
NOBELPHARMA AND EISAI ANNOUNCE JAPAN LAUNCH OF ANTINEOPLASTIC AGENT GLIADEL® 7.7 mg IMPLANT
January 8, 2013
EISAI SIGNS AGREEMENT WITH EPIZYME AND ROCHE MOLECULAR SYSTEMS TO DEVELOP COMPANION DIAGNOSTIC
January 7, 2013
NOVARTIS PHARMA AND EISAI TERMINATE CO-PROMOTION AGREEMENT FOR COPD THERAPIES
